Eli Lilly's top dealmaker says don't be surprised to see more M&A that pushes Lilly into new areas
Jacob Van Naarden is busy. In addition to running Eli Lilly's oncology business, he's now responsible for finding the drugmaker's next...
Centessa Pharmaceuticals PLC
Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit
Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time...
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Eli Lilly will acquire biotech company Kelonia Therapeutics in a deal worth up to $7 billion, the company said Monday.Lilly...
Lilly to spend up to $7.8 billion to acquire Centessa, a maker of experimental sleep disorder drugs
Eli Lilly Chair and CEO Dave Ricks speaks during a press conference in Houston, Texas, Sept. 23, 2025.Antranik Tavitian |...
Stocks making the biggest moves premarket: McCormick, Diageo, Nvidia & more
Check out the companies making the biggest moves premarket: McCormick — Shares rose more than 3% after Unilever confirmed it...
